SG2918 For Advanced Malignant Tumors
A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant Tumors
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Listed as NCT06167486, this PHASE1 trial focuses on Advanced Malignant Tumors and remains ongoing. Sponsored by Hangzhou Sumgen Biotech Co., Ltd., it has been updated 8 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hangzhou Sumgen Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Changsha, China
- • Chongqing, China
- • Hangzhou, China
- • Shanghai, China
- • Taiyuan, China
- • Zhengzhou, China